INMB: INmune Bio Inc Price to Sales
Global isolation of countries is hindering international testing of new drugs, which underscores the significance of the price-to-sales multiple. The value of 767.40 aligns with the current metric, capturing market expectations. However, sanctions and overseas patent complexities create risks for INmune Bio, Inc. (INMB). Meanwhile, colossal demand for Alzheimer's therapy opens vast growth prospects for the developer of selective inhibitors.
INmune Bio Corp (INMB) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- net income and valuation ratios data:
INMB - Net Profit|Expected Profit INmune Bio, Inc.|INMB - P/E Multiple|Market Cap to Projected Earnings INmune Bio Inc|INMB - Price/Earnings to Growth Ratio|Company Value to EBITDA INmune Bio Corp|INMB - Operating profit before deduction of amortization|Earnings per share for the trailing year INmune Bio|INMB - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months inmunebio.com|INMB - Earnings per share growth in current year|Projected earnings per share growth rate for next year INmune Bio, Inc.
- total revenue and sales volume data:
Fundamental company analysis:inmunebio.com (INMB)
P/S reflects the ratio of market capitalization to gross revenue, determining the cost per unit of revenue. Analyzing P/S volatility allows an investor to identify asset overbought conditions or the risk of capital freeze through historical context. This indicator is critical for assessing resource efficiency. For INmune Bio, Inc. (INMB), it reflects market expectations for future licensing deals with Big Pharma in the absence of current M&A strategies.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Price-to-Revenue Coefficient Protagonist Corp PTGX|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio KNSA|Price-to-Revenue Ratio Grifols|Market Cap to Revenue Adaptive Biotech (ADPT)|Market Cap to Revenue CLDX (Celldex)|P/S Multiple Aurinia Corp (AUPH)|Price-to-Revenue Ratio BioCryst BCRX|VERA: Market Cap to Revenue Ratio|Dianthus Therapeutics, Inc. - P/S Multiple|Price to Sales Pharvaris NV|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|Tourmaline - Market Capitalization-to-Revenue Ratio|PGEN (Precigen, Inc.) - P/S Multiple|Price-to-Revenue Ratio PHAR|P/S Multiple NKTR|Price-to-Revenue Coefficient Upstream Bio, Inc.|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Immunome Bio (IMNM) - Price to Sales|GOSS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio KALV (kalvista.com)|SEPN: P/S Multiple|PVLA - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Savara Corp|Market Cap to Revenue Ratio RIGL (Rigel Corp)|P/S Multiple ANAB|Market Cap to Revenue astriatx.com ATXS|enGene - Market Cap to Revenue|Price-to-Revenue Coefficient RAPT Therapeutics Inc. (RAPT)|Aerovate - P/S Multiple|Price-to-Revenue Coefficient Aclaris Therapeutics, Inc ACRS|Kyverna Therapeutics (KYTX) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio TLSA|Price-to-Revenue Ratio Cabaletta Bio|Market Cap to Revenue Ventyx Biosciences Inc. (VTYX)|P/S Multiple THTX|Price-to-Revenue Ratio AVTX (Avalo Therapeutics Inc)|Price-to-Revenue Ratio Eledon Pharmaceuticals ELDN|AGEN (agenusbio.com) - Price-to-Sales Ratio|Climb Bio - P/S Multiple|Market Capitalization-to-Revenue Ratio ZURA (Zura Bio Ltd)|ATYR: P/S Multiple|Adagene Inc. (ADAG) - P/S Multiple|Price-to-Revenue Ratio ImageneBio|STTK: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Equillium, Inc. (EQ)|Market Cap to Revenue connectbiopharm.com CNTB|P/S Multiple IMUX (Immunic)|P/S Multiple Atara Biotherapeutics, Inc. ATRA|IFRX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio XFOR (x4pharma.com)|ACET: P/S Multiple|CELU - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Barinthus Bio|Market Cap to Revenue Kezar Life Sciences Inc (KZR)|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|Market Cap to Revenue akaritx.com AKTX|Enlivex Therapeutics Ltd. - Market Cap to Revenue|P/S Multiple Q32 Bio Inc QTTB|GOVX - Price-to-Revenue Ratio|EDSA (Edesa Biotech Corp) - Market Cap to Revenue Ratio|IBIO: P/S Multiple|Price to Sales Carisma Therapeutics Inc. (CARM)|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|Bolt Bio (BOLT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|aptevotherapeutics.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX - Market Cap to Revenue|GRI: Market Cap to Revenue|XRTX - P/S Multiple|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio REVB|INDP (Indaptus Therapeutics) - P/S Multiple|Price to Sales scinai.com SCNI|Market Cap to Revenue CALI (CalciMedica, Inc.)|AFMD (affimed.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos)|HOOKIPA Pharma, Inc. - Price-to-Revenue Ratio|IGM Bio - P/S Multiple|Price-to-Revenue Coefficient iteostherapeutics.com ITOS|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|Price to Sales TC BioPharm (Holdings) Plc (TCBP)|Market Cap to Revenue THRD
